short bowel syndrome
UNASSIGNED: Subcutaneous teduglutide (Revestive(  )), a glucagon-like peptide-2 analogue that increases intestinal absorption, is approved in the EU for the treatment of short bowel syndrome (SBS) in patients aged >= 1  year who are stable following a period of postsurgical intestinal adaptation.